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Background: Colorectal cancer is the third most common cancer and a major cause of morbidity and mortality
worldwide. Adjuvant chemotherapy is considered the standard of care in patients with UICC stage III colon cancer
after R0 resection. Adjuvant therapy was not shown to be beneficial in patients with UICC stage II colon cancer.
However, there is an ongoing discussion as to whether adjuvant chemotherapy may be beneficial for a subgroup
of UICC II patients in a “high-risk situation” (such as T4).
Methods: We investigated a Bavarian population-based (2.1 million inhabitants) cohort of 1937 patients with UICC II
CRC treated between 2002 and 2012 in regard of the benefit of adjuvant chemotherapy for large (T4) tumors. Patients
older than 80 years of age were excluded. Of 1937 patients, 240 had a T4 tumor (12 %); 77 of all T4 patients received
postoperative chemotherapy (33 %). Kaplan-Meier analysis and Cox regression models were used for survival analyses.
Results: Patients with a T4 tumor who received postoperative chemotherapy had a highly significant survival benefit
in respect of overall survival (p < 0.001) and recurrence-free survival (p = 0.008). However, no difference was observed
between oxaliplatin-containing and non-oxaliplatin-containing treatment regimens. G2 and G3 tumors were found to
particularly benefit from adjuvant treatment. Chemotherapy, age at diagnosis, and tumor grading remained
independent risk factors in the multivariate cox regression analysis.
Conclusion: Our retrospective study demonstrated the significant benefit of adjuvant chemotherapy in the T4
subgroup of patients with UICC II colon cancer. Our data suggest that adjuvant chemotherapy should be seriously
considered in these patients.
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Colorectal cancer is the third most common cancer
and a major cause of morbidity and mortality worldwide
[1, 2]. With 55,000 to 60,000 newly diagnosed cases each
year, colorectal cancer ranks second among all cancer
types in Germany, and with more than 1 million new
cases it ranks third on a worldwide basis [3]. Advanced
therapy regimens and prevention programs in the last
few decades have definitely reduced mortality rates and
improved outcomes [4, 5]. Adjuvant chemotherapy was
found to enhance survival after curative surgery in patients
with lymph node-positive colon cancer. The MOSAIC trial,* Correspondence: andreas.teufel@ukr.de
†Equal contributors
1Department of Medicine I, University of Regensburg, Regensburg, Germany
Full list of author information is available at the end of the article
© 2015 Teufel et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.a milestone publication [6], established the combination
of 5-fluorouracil (5-FU), leucovorin and oxaliplatin
(FOLFOX4) as the standard adjuvant chemotherapy
regimen, replacing 5-FU and leucovorin in UICC-stage III
colon cancer-patients after R0 resection [6, 7].
However, the benefit of adjuvant therapy after R0
resection of colon cancer in UICC stage II remains unclear.
Summarizing several large studies and meta-analyses of
patients with stage II colon cancer, adjuvant therapy did
not prove beneficial in this group. Therefore, adjuvant
treatment is not routinely recommended in these patients
[8]. However, there is an ongoing discussion as to whether
adjuvant chemotherapy may be beneficial in a subgroup of
UICC II patients in a “high-risk situation”, such as those
with large tumors (T4) [9]. Therefore, despite the paucity of
appropriate data, the German clinical practice guidelinesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ered in these patients.
One reason for recommending adjuvant chemotherapy
in T4 UICC II tumors is the distinct biological behavior
of these cancers and their significantly poorer prognosis.
Regrettably, the potential benefit of adjuvant treatment
in patients with large (T4) tumors has not been spe-
cifically analyzed in any of the studies addressing the
role of adjuvant chemotherapy in patients with UICC
II stage colon cancer [10–12].
Therefore, we investigated an East-Bavarian cohort of
1937 patients who had undergone curative resection of
UICC II CRC in regard of the potential benefit of adjuvant
chemotherapy in patients with T4 tumors. The results of
our retrospective study point towards a significant benefit
of adjuvant treatment in these patients, and may help
to solve the current dilemma of deficient data on the
treatment of T4 UICC II colon cancer.
Methods
Study design
We performed a retrospective analysis of clinical data
obtained from the population-based cancer register at the
Regensburg Tumor Center in Eastern Bavaria, Germany.
Survival and recurrence rates were investigated in a cohort
of patients with R0-resected colon cancer, TNM stage
T4N0M0, diagnosed between 2002 and 2012. Patients
receiving adjuvant chemotherapy were compared to those
who had received no chemotherapy. Data collection
and the retrospective analysis of patient information
were anonymized in accordance with the Declaration
of Helsinki, and approved by the Bavarian Law of Cancer
Registration; the patients’ written informed consent was
not required.
Background and data collection
The Regensburg Tumor Center was founded in 1991.
The cancer registry includes epidemiological and clinical
data from all consenting patients with malignancies
diagnosed and treated by specialists as well as general prac-
titioners in the districts of Oberpfalz and Niederbayern in
Eastern Bavaria. The region covered by the center consists
of about 2.1 million inhabitants. More than 1000 practicing
doctors, the University Hospital of Regensburg, and
53 regional hospitals were involved in the area-wide,
population-based, cross-sector documentation of cancer
patients. The registry receives medical information from
all regional pathologists and clinicians at the time of diag-
nosis, treatment, and during follow-up. Physicians may
enter the data in case forms, use computer-assisted
tumor documentation, or send medical reports to the
registry. At the office of the registry the data are extracted,
recorded, and fed into a central database by suitably trained
personnel. The patients’ living status and disease recurrenceare ascertained from clinical reports, death certificates
issued by the local public health departments, and the
registration offices of the respective residential districts.
Data are processed and secured according to the Bavarian
Law of Cancer Registries. According to the estimates of
the German Robert-Koch institute (RKI), the Regensburg
Tumor Center includes more than 90 % of the estimated
number of cancer cases. Thus, the data were comprehen-
sive and selection bias was largely excluded.
The baseline cohort of the present study consisted
of patients with the ICD-10-GM (https://www.dimdi.de/
static/de/klassi/icd-10-gm) diagnosis C18, i.e. a malignant
neoplasm of colon. Patients with histologically confirmed
adenocarcinoma from 2002 to 2012 were included in
the study (Additional file 1: Fig. S1). Neuroendocrine
tumors were excluded. The TNM stage according
to the UICC classification of malignant tumors was IIB,
corresponding to T4N0M0. In other words, the tumor
had invaded adjacent organs or penetrated the visceral
peritoneum, with no distant metastases and/or regional
lymph node metastases. Only patients who had under-
gone surgery for pathologically confirmed total or local
residual R0 disease were included. Since a preceding
evaluation had revealed that chemotherapy was admin-
istered to only one patient older than 79 years of age,
the analysis was confined to patients younger than
80 years at the time of diagnosis. Patients who died
within 30 days after the diagnosis were excluded, as
chemotherapy could not be used effectively in these
patients.
Statistical analysis
Continuous data are described as means, median,
minimum, maximum values and standard deviation,
and categorical data are expressed as absolute frequencies
and relative percentages. Patient characteristics were com-
pared with T-tests for continuous data, and Chi-square
tests for categorical variables. Life status for estimating
overall survival rates was derived from clinical reports,
death certificates, and registration offices. Recurrences
were derived from clinical reports and were defined
as locoregional relapse and/or recurrence as distant
metastases. Overall survival rates (OS), recurrence-free
survival rates (RFS), and cumulative recurrence rates were
analyzed from the date of diagnosis until the first event.
Patients with and without adjuvant chemotherapy were
compared with the Kaplan-Meier method. The follow-up
period and survival times were right censored using 31
December 2012 as the cut-off date. Survival differences
were tested for statistical significance by the two-sided
log rank test; the level of significance was set to 0.05.
To determine the influence of adjuvant chemotherapy
and further covariables on overall survival, we performed
univariate and multivariate regression analysis using
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the hazard ratio (HR) of chemotherapy versus no chemo-
therapy was adjusted for the covariables of age, sex,
postoperative histopathological grading, and the number
of lymph nodes. Again, a two-sided p-value of 0.05 was
considered to indicate statistical significance. Hazard
ratios and corresponding 95 % confidence intervals (CI)
were calculated and considered statistically significant
when the CI excluded 1.0.
All analyses were performed using IBM SPSS Statistics,
version 21.0.
Results
Characterization of patients with and without adjuvant
chemotherapy for T4 UICC II colon cancer
Of 240 patients with T4 UICC II colon cancer, 79 had
received adjuvant treatment after surgery (32.9 %); their
mean age was 63.9 years (median, 66.5 years). Patients
who received no adjuvant chemotherapy were on
average 68.3 years old (median 69.5, p = 0.002). The
large majority of patients had cancer of the sigmoid
colon (30.4 %). The overall number of patients with
cancers in the various locations of the colon were
similar in those with and without adjuvant chemo-
therapy. The cancer was located more frequently in
the sigmoid colon in patients who received adjuvant
therapy; the difference was not significant (p = 0.258).
The grading of tumors was similar in the two groups
(p = 0.254). Besides, a larger number of patients who
had received adjuvant treatment were alive at the time of
data analysis (82.3 % vs. 65.2 %, p = 0.006, Table 1).
The mean duration of follow-up was 47.2 months
(median 48.2 months).
Differences in overall and recurrence-free survival in T4
UICC II patients with or without adjuvant chemotherapy
We investigated differences in overall survival in relation
to adjuvant chemotherapy in T4 UICC II colon cancer
patients. Overall survival improved significantly in patients
who received adjuvant therapy (p < 0.001), with 5-year sur-
vival rates of 81.7 % vs. 51.7 % (Fig. 1, Table 2). Cumulative
overall recurrence rates in the former group were slightly
higher but did not differ significantly (p = 0.700, Table 2,
Additional file 2: Fig. S2, Additional file 3: Table S1); nor
did the rates estimated separately for locoregional recur-
rences and distant metastases (Additional file 4: Table S2).
Kaplan-Meier estimates of recurrence-free survival
yielded a 5-year survival rate of 68.2 % in treated,
versus 45.9 % in untreated patients, showing the sig-
nificant benefit of adjuvant chemotherapy (p = 0.008.
Table 2, Additional file 2: Fig. S2, Additional file 5:
Table S3).
The results of the Kaplan-Meier estimates were con-
firmed by Cox proportional hazard analyses. In univariateand multivariate models (adjusted for age at diagnosis, sex,
grading, number of examined lymph nodes, lymph vessel
invasion, vein invasion), adjuvant chemotherapy persisted
as an independent significant factor influencing overall
survival (adjusted HR 0.41, p = 0.001) and recurrence-free
survival (adjusted HR = 0.55, p = 0.010). Of the studied
variables, only the number of examined lymph nodes
(p < 0.001) and tumor grading (p = 0.014) remained inde-
pendent factors besides chemotherapy (Table 3).
In order to fully estimate the impact of adjuvant chemo-
therapy in T4 UICC II patients, we initially excluded pa-
tients who died within 30 days after surgery. These
patients were likely to have died due to non-cancer-
related reasons. Besides, chemotherapy could not be
effectively applied or develop its potential in this
group. The significant benefit of adjuvant chemother-
apy in regard of overall survival persisted when the
additional sub-analyses excluded patients who died within
60 and 90 days after diagnosis, all of them occurring in
the non-treatment group (Table 2, Additional file 6:
Fig. S3).Survival benefit in relation to the drugs administered as
adjuvant treatment for T4 UICC II cancer
Once the decision to administer adjuvant treatment
has been made, the choice of drugs needs to be deter-
mined. Specifically, one needs to decide whether to use
5-fluorouracil alone or with additional oxaliplatin. We
divided our T4 UICC II patients who had received
adjuvant chemotherapy into additional subgroups, de-
pending on the drugs they had received. The three
groups, i.e. FUFOL (n = 15), FUFOL + oxaliplatin (n = 27),
and “other substances” (n = 22), contained more than 10
patients each and were therefore considered for individual
analyses; 161 patients remained untreated. As the
numbers of patients in the three subgroups remained low,
the subgroup analyses must be considered exploratory.
However, patients receiving treatment showed a significant
benefit in terms of overall survival (p = 0.041 for FUFOL,
p = 0.047 for FUFOL + oxaliplatin, and p = 0.037 for “other
drugs”, Fig. 1d, Table 4, Additional file 7: Table S4)
compared to untreated patients. Thus, the choice of drugs
seemed to be of secondary importance for the achieve-
ment of a survival benefit.Influence of tumor grading on survival in T4 UICC II cancers
In order to determine a potential indication for adju-
vant chemotherapy, patients were additionally strati-
fied on the basis of tumor grading. T4 UICC II
patients with G3 cancers benefited to a significantly
greater extent from adjuvant chemotherapy (5-year OS
68.9 % vs. 23.4 %, p = 0.014, Table 2, Fig. 2). Furthermore,
survival was significantly improved in G2 T4 UICC II
Table 1 Clinical characteristics of patients with T4 UICC II colon cancer. Patients over 80 years of age and those who died within
30 days after the diagnosis were excluded
Chemotherapy
+ CTX − CTX Total Chi square
N % N % N % p-value
Sex male 47 59.5 % 97 60.2 % 144 60.0 % 0.910697
female 32 40.5 % 64 39.8 % 96 40.0 %
Age at diagnosis 30–39 2 2.5 % 1 0.6 % 3 1.3 %
40–49 7 8.9 % 9 5.6 % 16 6.7 %
50–59 16 20.3 % 14 8.7 % 30 12.5 % 0.030225
60–69 28 35.4 % 61 37.9 % 89 37.1 %
70–79 26 32.9 % 76 47.2 % 102 42.5 %
Diagnosis ICD-10 C18.0 caecum 14 17.7 % 31 19.3 % 45 18.8 %
C18.1 appendix 3 3.8 % 5 3.1 % 8 3.3 %
C18.2 ascending colon 14 17.7 % 23 14.3 % 37 15.4 %
C18.3 hepatic flexure 2 2.5 % 14 8.7 % 16 6.7 %
C18.4 transverse colon 5 6.3 % 18 11.2 % 23 9.6 % 0.258347
C18.5 splenic flexure 3 3.8 % 11 6.8 % 14 5.8 %
C18.6 descending colon 5 6.3 % 11 6.8 % 16 6.7 %
C18.7 sigmoid colon 32 40.5 % 41 25.5 % 73 30.4 %
C18.8 overlapping sites of colon 1 1.3 % 6 3.7 % 7 2.9 %
C18.9 colon. unspecified 0 0.0 % 1 0.6 % 1 0.4 %
Grading 2 56 70.9 % 125 77.6 % 181 75.4 % 0.253519
3 23 29.1 % 36 22.4 % 59 24.6 %
Lymphnodes examined 1–11 4 5.1 % 11 6.8 % 15 6.3 %
12–23 44 55.7 % 95 59.0 % 139 57.9 % 0.806346
24+ 30 38.0 % 52 32.3 % 82 34.2 %
unknown 1 1.3 % 3 1.9 % 4 1.7 %
Lymph vessel invasion L0 30 38.0 % 62 38.5 % 92 38.3 % 0.758440
L1 37 46.8 % 69 42.9 % 106 44.2 %
LX 12 15.2 % 30 18.6 % 42 17.5 %
Vein invasion V0 53 67.1 % 92 57.1 % 145 60.4 % 0.068554
V1 12 15.2 % 18 11.2 % 30 12.5 %
VX 14 17.7 % 51 31.7 % 65 27.1 %
Recurrence no 63 79.7 % 138 85.7 % 201 83.8 % 0.238964
yes 16 20.3 % 23 14.3 % 39 16.3 %
Locoregional recurrence no 72 91.1 % 154 95.7 % 226 94.2 % 0.160988
yes 7 8.9 % 7 4.3 % 14 5.8 %
Distant recurrence no 67 84.8 % 146 90.7 % 213 88.8 % 0.176026
yes 12 15.2 % 15 9.3 % 27 11.3 %
Vital status alive 65 82.3 % 105 65.2 % 170 70.8 % 0.006285
dead 14 17.7 % 56 34.8 % 70 29.2 %
Death or recurrence no 58 73.4 % 95 59.0 % 153 63.8 % 0.029079
yes 21 26.6 % 66 41.0 % 87 36.3 %
Total 79 100.0 % 161 100.0 % 240 100.0 %
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Fig. 1 a. ‘A larger number of younger patients with T4 UICC stage II received adjuvant chemotherapy. b. The location of disease did not differ
significantly between treated and untreated patients. c. Overall survival benefit for T4 UICC II colon cancer patients who received adjuvant
chemotherapy (p < 0.001). d. All of the of adjuvant treatments used (5-Fluorouracil and folinic acid (FUFOL), FUFOL and oxaliplatin, Capecitabin
and Oxaliplatin, and Capecitabine) appear to be beneficial compared to patients not receiving adjuvant chemotherapy. Patients over 80 years
of age and those who died within 30 days after the diagnosis were excluded
Teufel et al. BMC Cancer  (2015) 15:419 Page 5 of 9tumors (5-year OS 87.0 % vs. 60.0 %, p = 0.009, Table 2,
Fig. 2).
No influence of age at diagnosis on survival in T4 UICC II
CRC patients
Besides tumor grading, the influence of the patient’s
age at diagnosis on survival was investigated in T4
UICC II patients with colon cancer. In the small
number of patients younger than 60 years of age, we
observed a slight but non-significant trend in favor of
adjuvant chemotherapy (p = 0.726). In contrast, an
additional survival benefit due to adjuvant chemotherapy
was observed in patients aged 60 to 69 years and those
between 70 and 79 years, the difference being significant
only in the younger age group [p = 0.011 (60–69 years);
p = 0.064 (70–79 years), Additional file 8: Fig. S4].Discussion
Generally, the prognosis of disease is considered favorable
in patients with UICC stage II colon cancer who have
undergone R0 resection; adjuvant therapy is currently not
recommended in these patients. The absolute benefit of
adjuvant therapy in patients with UICC stage II CRC
without additional risk factors ranges between 2 % and
5 %. Overall however, studies and meta-analyses in
patients with stage II colon cancer revealed no significant
survival advantage [10, 11, 13, 14]. A pooled analysis of
seven randomized trials comparing adjuvant chemother-
apy with surgery alone showed, in univariate analysis, a
significant improvement of 5-year disease-free survival
(DFS) (72 % versus 76 %; p = 0.049), but not 5-year overall
survival (80 % versus 81 %; p = 0.1127). However, the
therapy regimens varied significantly in these studies and
Table 2 Overall survival rates OAS (Kaplan-Meier) of patients with T4 UICC II colorectal cancer. Patients over 80 years of age
were excluded
Group Chemotherapy Number Overall survival rate OAS Log-Rank
Total Events 5 years (%) Median OAS (m) P-value
All patients (deceased within 30 days excluded) + CTX 79 14 81.7 − <0.001
−CTX 161 56 51.7 63.3
Deceased within 60 days excluded + CTX 79 14 81.7 − 0.002
−CTX 156 51 53.7 79.3
Deceased within 90 days excluded + CTX 79 14 81.7 95.5 0.006
−CTX 152 47 55.4 79.3
Age at diagnosis < 60 years + CTX 25 5 90.9 −
−CTX 24 4 70.0 − 0.726
Age at diagnosis 60 − 69 years + CTX 28 4 77.8 − 0,011
−CTX 61 25 44.9 53.5
Age at diagnosis 70–79 years + CTX 26 5 77.0 – 0.064
−CTX 76 27 52.0 63.6
Tumor grading G2 + CTX 56 8 87.0 − 0.009
−CTX 125 39 60.0 89.0
Tumor grading G3 + CTX 23 6 68.9 95.5 0.014
−CTX 36 17 23.4 42.9
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patients. In contrast, adjuvant treatment was found to
yield a significant benefit in the QUASAR study [12],
which is the largest study investigating the role of adjuvant
chemotherapy in UICC II cancer. In view of these contro-
versial data, the potential benefit of adjuvant chemotherapyTable 3 Multivariate Cox regression for overall survival in patients w
80 years of age were excluded
Variable Value p value
Chemotherapy −CTX
+CTX 0.005














VX 0.054for specific subgroups of patients with UICC II CRC
and especially those with additional risk factors is still
controversially discussed. [12] These risk factors include
lymph node sampling below 12, a poorly differentiated
tumor, vascular or lymphatic or perineural invasion, a pT4
stage, and intestinal occlusion or perforation on clinicalith R0 resected T4 UICC II colorectal cancer. Patients over





























Chemotheraphy Chi- Chi- Chi- Chi- Chi- Chi-
group square Sig. square Sig. square Sig. square Sig. square Sig. square Sig.
Long Rank FUFOL ,072 ,788 . . ,013 ,909 ,563 ,453 4,179 ,041
(Mantel-Cox) FUFOL + Oxaliplatin ,072 ,788 ,074 ,785 ,192 ,661 ,015 ,901 3,934 ,047
Others + Oxaliplatin . . ,074 ,785 ,118 ,732 . . ,628 ,428
Other substances ,013 ,909 ,192 ,661 ,118 ,732 ,223 ,636 4,370 ,037
Substance unknown ,563 ,453 ,015 ,901 ,223 ,636 ,681 ,409
No chemotheraphy 4,179 ,041 3,934 ,047 ,628 ,428 4,370 ,037 ,681 ,409
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have suggested adjuvant therapy for these patients, we
lack data concerning the benefit of adjuvant therapy in
this subgroup. Furthermore, once the decision in favor
of adjuvant treatment has been made, the choice of
drugs - 5-fluorouracil with or without oxaliplatin – is
a debated issue. Data from the MOSAIC [6] and the
NSABP protocol C05-C08 trials indicated a borderline
benefit of 2–3 % in 5-year OS rates when using additional
oxaliplatin [15]. Therefore, we assessed the benefit of
adjuvant chemotherapy in a large cohort of T4 UICC
II patients within a specific region of Germany.
Among our patients with T4 UICC II tumors, those
who received chemotherapy were significantly younger
(p = 0.002) and had a (non-significant) larger number of
G3 tumors (p = 0.286). This difference between treated
and untreated patients may assist the clinician in selecting
patients for adjuvant chemotherapy. Since patients overFig. 2 Kaplan Meier estimates for overall survival in patients with R0 resect
with G2 (a, p = 0.009) and G3 (b, p = 0.014) tumors benefited significantly fr80 years of age rarely received adjuvant chemotherapy, we
excluded these patients from analysis. For all others, the
difference in age at diagnosis may potentially influence
patient survival because older patients may have more
severe co-morbidities. Therefore we performed separate
survival analyses in the age groups <60 years, 60–69 years,
and 70–79 years at diagnosis. The difference in survival
could also be observed in the 60- to 69-year and 70- to
79-year-old groups. Among patients under 60 years of
age, we noted a slight benefit of adjuvant chemotherapy.
However, this group consisted of a small number of
patients. Besides, the significant results of the univariate
Cox regression analysis persisted in a multivariate regres-
sion analysis with adjustment for age at diagnosis.
Patients with perioperative mortality are less likely to
receive adjuvant chemotherapy, but may have shorter
survival times. To rule out the influence of perioperative
mortality or even mortality on our analysis, we excludeded T4 UICC II colorectal cancer, depending on tumor grading. Patients
om adjuvant chemotherapy
Teufel et al. BMC Cancer  (2015) 15:419 Page 8 of 9patients with events within the first 30, 60, and 90 days
after diagnosis. All three analyses showed a significant
benefit for patients treated with adjuvant chemotherapy
(Fig. 1, Additional file 8: Fig. S4). Thus, perioperative
mortality had no impact on the analysis. Although the
cumulative rates for recurrent events were slightly but
non-significantly higher among patients who received
adjuvant chemotherapy, the benefit persisted in this
group in respect of recurrence-free survival.
Drawback of our approach was that the reports did
not contain details about side effects under treatment.
However, all chemotherapy regimens used for adjuvant
treatment were well established drug combinations
routinely used in UICC stage III CRC. Therefore, we con-
sidered all of the employed chemotherapy regimens as
feasible and generally well tolerated.
Overall, our data demonstrated the significant benefit
of adjuvant chemotherapy in patients with T4 UICC II
colon cancer. Since our findings suggested a change
in the current treatment recommendations, we per-
formed further subgroup analyses excluding the influ-
ence of age or perioperative morbidity. Based on our
data we conclude that adjuvant chemotherapy is
justified in T4 UICC II patients. Further prospective
studies should be performed to obtain confirmation
of this thesis.Conclusion
A retrospective investigation showed the significant benefit
of adjuvant chemotherapy in T4 UICC II patients. Based
on our data, adjuvant chemotherapy should be seriously
considered in T4 UICC II patients with colon cancer.
Tumor grading may also influence the benefit of adjuvant
treatment and warrants further investigation.Additional files
Additional file 1: Figure. S1. Patients with T4 UICC II and adjuvant
treatment, separated per year between 2002 and 2012.
Additional file 2: Figure. S2. Comparison of cumulative 10-year
recurrence rates in patients with and without adjuvant chemotherapy after R0
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Additional file 4: Table S2. Cumulative recurrence rates (Kaplan-Meier)
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Additional file 6: Figure. S3. Recurrence-free survival of patients in
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excluding all events 90 days after surgery (B): the significant benefit of
adjuvant chemotherapy was noted in both groups.Additional file 7: Table S4. Listing of additional chemotherapies after
recurrence of disease.
Additional file 8: Figure. S4. Survival of patients with T4 UICC II
tumors and different ages at diagnosis. Among patients younger than
60 years (A), we observed a trend in favor of chemotherapy. However,
the group consisted of a small number of patients. A significant
difference in favor of chemotherapy was noted among patients aged
60–69 years at diagnosis (B), and a marginally non-significant difference
in patients aged 70–79 years (C).
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